Results 21 to 30 of about 216,339 (397)

Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

Clinical Cancer Research, 2023
Purpose: Glioblastoma represents the most common primary brain tumor. Although antiangiogenics are used in the recurrent setting, they do not prolong survival.
W. Kelly, A. D. Diaz Duque, Joel Michalek, Brandon Konkel, Laura Caflisch, Yidong Chen, S. Pathuri, Vinu Madhusudanannair Kunnuparampil, J. Floyd, A. Brenner   +9 more
semanticscholar   +1 more source

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

Liver Cancer, 2023
Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda   +13 more
doaj   +1 more source

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Hepatology, 2022
Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function.
A. D’Alessio, C. Fulgenzi, N. Nishida, Martin Schönlein, J. von Felden, K. Schulze, H. Wege, V. Gaillard, A. Saeed, B. Wietharn, H. Hildebrand, Linda Wu, C. Ang, T. Marron, A. Weinmann, P. Galle, D. Bettinger, B. Bengsch, A. Vogel, L. Balcar, B. Scheiner, Pei‐Chang Lee, Yi‐Hsiang Huang, Suneetha Amara, M. Muzaffar, A. Naqash, A. Cammarota, N. Personeni, T. Pressiani, Rohini Sharma, M. Pinter, A. Cortellini, M. Kudo, L. Rimassa, D. Pinato   +34 more
semanticscholar   +1 more source

Bevacizumab for recurrent ependymoma [PDF]

Neurology, 2009
2060 Background: Ependymoma is a rare type of glioma, representing less than 5% of brain tumors in adults. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. At recurrence ependymoma is notoriously refractory to therapy and the prognosis is poor.
Andrew B. Lassman, Richard M. Green, Emily Woyshner, Douglas E. Ney, Douglas E. Ney, Lisa M. DeAngelis, Timothy F. Cloughesy, Roger Stupp   +7 more
openaire   +4 more sources

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits [PDF]

International Journal of Ophthalmology, 2015
AIM:To investigate the pharmacokinetics and distributions of bevacizumab by intravitreal injection of prepared bevacizumab-poly (L-lactic-co-glycolic acid) (PLGA) microspheres in rabbits, to provide evidence for clinical application of this kind of ...
Zhuo Ye, Yan-Li Ji, Xiang Ma, Jian-Guo Wen, Wei Wei, Shu-Man Huang   +5 more
doaj   +1 more source

Bevacizumab for the Treatment of Glioblastoma

Clinical Medicine Insights: Oncology, 2013
Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors
J. Gil-gil, Miguel, Mesia, Carlos, Rey, Montserrat, Bruna, Jordi   +3 more
openaire   +10 more sources

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Cancer Medicine, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference bevacizumab (EU‐bevacizumab) in patients with advanced nonsquamous non‐small cell lung cancer (
Likun Chen, Jose David Gomez Rangel, Timucin Cil, Xingya Li, Irfan Cicin, Yihong Shen, Zhihua Liu, Ozgur Ozyilkan, Bondarenko Igor, Jun Chen, Kostiuk Oleksandr, Zhendong Chen, Helong Zhang, Ziyi Fu, Qingfeng Dong, Shuqiang Song, Jin‐Chen Yu, Li Zhang   +17 more
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Pharmaceuticals, 2020
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA.
Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Kosuke Takigawa, Masahiro Mizoguchi   +7 more
doaj   +1 more source

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

JAMA Oncology, 2020
Key Points Question Does programmed cell death 1 immune checkpoint inhibition with nivolumab improve overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma?
D. Reardon, A. Brandes, A. Omuro, P. Mulholland, M. Lim, A. Wick, J. Baehring, M. Ahluwalia, P. Roth, O. Bähr, S. Phuphanich, J. Sepúlveda, Paul De Souza, S. Sahebjam, M. Carleton, K. Tatsuoka, C. Taitt, R. Zwirtes, J. Sampson, M. Weller   +19 more
semanticscholar   +1 more source